Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease.
10.1007/s11655-019-2701-y
- Author:
Hao XU
1
;
Zhuo CHEN
1
;
Qing-Hua SHANG
1
;
Zhu-Ye GAO
1
;
Chang-An YU
2
;
Da-Zhuo SHI
1
;
Ke-Ji CHEN
3
Author Information
1. Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. Department of Cardiology, China-Japan Friendship Hospital, Beijing, 100029, China.
3. Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. kjchenvip@163.com.
- Publication Type:Journal Article
- Keywords:
asymmetric dimethylarginine;
coronary heart disease;
nested case-control study;
recurrent cardiovascular event;
toxin syndrome
- MeSH:
Arginine;
analogs & derivatives;
blood;
Biomarkers;
blood;
Coronary Disease;
blood;
Humans;
Odds Ratio;
ROC Curve;
Recurrence;
Risk Factors;
Syndrome
- From:
Chinese journal of integrative medicine
2019;25(5):327-333
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD.
METHODS:In this prospective nested case-control study, 36 of 1,503 Chinese patients with stable CHD experienced at least 1 recurrent cardiovascular event (RCE) during 1-year follow-up. Serum levels of ADMA at the start of follow-up were compared between these 36 cases and 36 controls which matched to cases in terms of gender, age, history of hypertension, and myocardial infarction.
RESULTS:Based on the crude model, subjects in the 2 highest ADMA quartiles showed significantly higher risk of developing RCE than those in the lowest ADMA quartile [odds ratio (OR) 4.09, 95% confidence interval (CI) 1.01 to 16.58; OR 6.76, 95% CI 1.57 to 29.07]. This association was also observed in the case-mix model (OR 5.51, 95% CI 1.23 to 24.61; OR 7.83, 95% CI 1.68 to 36.41) and multivariable model (OR 6.64, 95% CI 1.40 to 31.49: OR 13.14, 95% CI 2.28 to 75.71) after adjusting for confounders. The multivariable model which combined ADMA and high-sensitivity C-reactive protein (hsCRP) showed better predictive power with areas under the receiver operator characteristic curves (0.779) than the model of either ADMA (0.694) or hsCRP (0.636).
CONCLUSION:Serum ADMA level may be a potential biomarker of "toxin syndrome" in CHD which shows favorable prognostic value in predicting 1-year RCE in patients with stable CHD. [The registration number is ChiCTR-PRNRC-07000012].
